ZENBEXUS Drug Patent Profile

Name: ZENBEXUS Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which patents cover Zenbexus, and what generic alternatives are available?

Zenbexus is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in ZENBEXUS is iberdomide hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the iberdomide hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zenbexus

Zenbexus will be eligible for patent challenges on August 13, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 7, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ZENBEXUS?
What are the global sales for ZENBEXUS?
What is Average Wholesale Price for ZENBEXUS?

Summary for ZENBEXUS

US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	534
What excipients (inactive ingredients) are in ZENBEXUS?	ZENBEXUS excipients list
DailyMed Link:	ZENBEXUS at DailyMed

Drug patent expirations by year for ZENBEXUS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZENBEXUS

Generic Entry Date for ZENBEXUS^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: ⤷ Start Trial NDA: 221075 Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZENBEXUS

ZENBEXUS is protected by seven US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZENBEXUS is ⤷ Start Trial.

This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-002	Aug 13, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-002	Aug 13, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-002	Aug 13, 2026		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial		Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZENBEXUS

When does loss-of-exclusivity occur for ZENBEXUS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 0663
Patent: FORMULACIONES DE (S)-3-(4-((4-(MORFOLINOMETIL)BENCIL)OXI)-1-OXOISOINDOLIN-2-IL)PIPERIDIN-2,6-DIONA
Estimated Expiration: ⤷ Start Trial

Australia

Patent: 14332171
Patent: Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Estimated Expiration: ⤷ Start Trial

Brazil

Patent: 2016007729
Patent: FORMA DE DOSAGEM COMPREENDENDO (S)-3-(4-((4- (MORFOLINOMETIL)BENZIL)ÓXI)-1-OXOISOINDOLIN-2-IL)PIPERIDINA-2,6- DIONA E KIT QUE A COMPREENDE
Estimated Expiration: ⤷ Start Trial

Canada

Patent: 21436
Patent: FORMULATIONS DE (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

Chile

Patent: 16000816
Patent: Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
Estimated Expiration: ⤷ Start Trial

China

Patent: 5899196
Estimated Expiration: ⤷ Start Trial

Costa Rica

Patent: 160131
Patent: FORMULACIONES DE (S)-3-(4- ((4- (MORFOLINOMETIL)BENZIL) OXI) -1-OXOISOINDOLIN)-2-IL) PIPERIDIN -2,6-DIONA
Estimated Expiration: ⤷ Start Trial

Croatia

Patent: 0190733
Estimated Expiration: ⤷ Start Trial

Cyprus

Patent: 21689
Estimated Expiration: ⤷ Start Trial

Denmark

Patent: 54927
Estimated Expiration: ⤷ Start Trial

Eurasian Patent Organization

Patent: 2421
Patent: СОСТАВЫ (S)-3-(4-((4-(МОРФОЛИНОМЕТИЛ)БЕНЗИЛ)ОКСИ)-1-ОКСОИЗОИНДОЛИН-2-ИЛ)ПИПЕРИДИН-2,6-ДИОНА (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

Patent: 1690741
Patent: СОСТАВЫ (S)-3-(4-((4-(МОРФОЛИНОМЕТИЛ)БЕНЗИЛ)ОКСИ)-1-ОКСОИЗОИНДОЛИН-2-ИЛ)ПИПЕРИДИН-2,6-ДИОНА (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

European Patent Office

Patent: 54927
Patent: FORMULATIONS DE (S)-3-(4-((4-(MORPHOLINOMÉTHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

Hungary

Patent: 44186
Estimated Expiration: ⤷ Start Trial

Israel

Patent: 4494
Patent: פורמולציות של 3–(4–((4–(מורפולינומתיל)בנזיל) אוקסי)–1–אוקסואיזואינדולין–2–איל)פיפרידין–6,2–דיאון (Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione)
Estimated Expiration: ⤷ Start Trial

Japan

Patent: 62907
Estimated Expiration: ⤷ Start Trial

Patent: 16532657
Patent: （Ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの製剤
Estimated Expiration: ⤷ Start Trial

Lithuania

Patent: 54927
Estimated Expiration: ⤷ Start Trial

Mexico

Patent: 16004342
Patent: FORMULACIONES DE (S)-3-(4-((4-MORFOLINOMETIL)BENCIL)OXI)-1-OXOISOI NDOLIN-2-IL)PIPERIDIN-2,6-DIONA. (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOIS OINDOLIN-2-YL)PIPERIDINE-2,6-DIONE.)
Estimated Expiration: ⤷ Start Trial

New Zealand

Patent: 6856
Patent: Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Estimated Expiration: ⤷ Start Trial

Nicaragua

Patent: 1600048
Patent: FORMULACIONES DE (S)- 3- (4-((4-(MORFOLINOMETIL) BENCIL)OXI)-1-OXOISOINDOLIN-2-IL) PIPERIDIN-2, 6-DIONA
Estimated Expiration: ⤷ Start Trial

Peru

Patent: 160550
Patent: FORMULACIONES DE (S)-3-(4-((4-(MORFOLINOMETIL)BENCIL)OXI)-1-OXOISOINDOLIN-2-IL)PIPERIDIN-2,6-DIONA
Estimated Expiration: ⤷ Start Trial

Philippines

Patent: 016500301
Patent: FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
Estimated Expiration: ⤷ Start Trial

Poland

Patent: 54927
Estimated Expiration: ⤷ Start Trial

Portugal

Patent: 54927
Estimated Expiration: ⤷ Start Trial

San Marino

Patent: 01900231
Estimated Expiration: ⤷ Start Trial

Saudi Arabia

Patent: 6370860
Patent: صيغ من مركب (S) -3- (4- ((4- (موورفولينو ميثيل) بنزيل) أوكسي) -1- أوكسو أيزو إندولين -2- يل) ببريدين -2، 6- دايون) (Formulations of (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

Serbia

Patent: 688
Patent: FORMULACIJE (S)-3-(4-((4-(MORFOLINOMETIL)BENZILOKSI)-1-OKSOIZOINDOLIN-2-IL)PIPERIDIN-2,6-DIONA (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

Singapore

Patent: 201600996U
Patent: FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
Estimated Expiration: ⤷ Start Trial

Slovenia

Patent: 54927
Estimated Expiration: ⤷ Start Trial

South Korea

Patent: 2272274
Estimated Expiration: ⤷ Start Trial

Patent: 160067118
Patent: 피페리딘-2,6-디온의 제제 (-3-4-4--1--2--26- FORMULATIONS OF -3-4-4-MORPHOLINOMETHYLBENZYLOXY-1-OXOISOINDOLIN-2-YLPIPERIDINE-26-DIONE)
Estimated Expiration: ⤷ Start Trial

Spain

Patent: 23891
Estimated Expiration: ⤷ Start Trial

Taiwan

Patent: 1605493
Patent: Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Estimated Expiration: ⤷ Start Trial

Turkey

Patent: 1905874
Estimated Expiration: ⤷ Start Trial

Ukraine

Patent: 7141
Patent: СКЛАДИ (S)-3-(4-((4-(МОРФОЛІНОМЕТИЛ)БЕНЗИЛ)ОКСІ)-1-ОКСОІЗОІНДОЛІН-2-ІЛ)ПІПЕРИДИН-2,6-ДІОНУ (FORMULATIONS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYLOXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE)
Estimated Expiration: ⤷ Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZENBEXUS around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2019351811	Combination therapy for the treatment of cancer	⤷ Start Trial
Brazil	112021006318	terapia de combinação para o tratamento de câncer	⤷ Start Trial
Canada	3114401	POLYTHERAPIE POUR LE TRAITEMENT DU CANCER (COMBINATION THERAPY FOR THE TREATMENT OF CANCER)	⤷ Start Trial
China	112839658	用于治疗癌症的组合疗法 (COMBINATION THERAPY FOR THE TREATMENT OF CANCER)	⤷ Start Trial
Eurasian Patent Organization	202190865	КОМБИНИРОВАННАЯ ТЕРАПИЯ ДЛЯ ЛЕЧЕНИЯ РАКА	⤷ Start Trial
European Patent Office	3860610	POLYTHÉRAPIE POUR LE TRAITEMENT DU CANCER (COMBINATION THERAPY FOR THE TREATMENT OF CANCER)	⤷ Start Trial
Israel	281845	טיפול משולב לטיפול בסרטן (Combination therapy for the treatment of cancer)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

AI Deep Research

Questions you can ask:

Summary for ZENBEXUS

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZENBEXUS

When does loss-of-exclusivity occur for ZENBEXUS?

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZENBEXUS